Bristol Myers Squibb Co. closed 6.82% below its 52-week high of $63.33, which the company reached on March 11th.
Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...
Morgan Stanley lowered the firm’s price target on 2seventy Bio (TSVT) to $5 from $6 and keeps an Equal Weight rating on the shares following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback